Now, with a pipeline chock-full of numerous incretin therapies, the Big Pharma's new strategy will be to test some of those drugs across neurology and immunology indications. "A new focus area ...

Management expects significant contributions from U.S. incretin class growth and international Mounjaro launches. Earnings per share (EPS) for 2025 are projected at $22.50 to $24.00. Management ...

Eli Lilly LLY1.93%increase; green up pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...

"While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration of growth for the quarter,” the CEO noted at the time.

CCK denotes cholecystokinin, GI gastrointestinal, GLP-1 glucagon-like peptide 1, and PYY peptide YY. Hunger is controlled by redundant neuroendocrine circuitries that maintain metabolic balance.

The issue seems to come down to the fact that the market for incretin meds like Lilly’s Mounjaro and Zepbound is growing, but not nearly as fast as the company—or industry watchers—had expected.

The forecast is "likely less a shock to investors but may still shake some confidence in incretin demand," said BMO Capital Markets analyst Evan Seigerman, referring to the class of drugs that ...

ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals. We sell different ...